Optical Quality, Threshold Target Identification, and Military Target Task Performance After Advanced Keratorefractive Surgery



Status:Recruiting
Conditions:Ocular
Therapuetic Areas:Ophthalmology
Healthy:No
Age Range:21 - 55
Updated:10/19/2013
Start Date:April 2010
Contact:Lamarr Peppers
Email:lamarr.peppers1@us.army.mil
Phone:571-231-1600

Use our guide to learn which trials are right for you!


To determine the effect of two types of wavefront modalities (WFG vs. WFO) and two types of
refractive surgery (PRK vs. LASIK) on visual and military task performance after laser
refractive surgery.


Inclusion Criteria:

1. Normal, healthy active adults with access to medical care at Walter Reed Health Care
System.

2. Male or female at least 21 years old at the time of the pre-operative examination,
and have signed an informed consent. The lower age limit of 21 years is intended to
ensure documentation of refractive stability.

3. Myopic spherical manifest refractive error from -1.00D up to -10.00D inclusive, with
no more than 4.00D of manifest cylinder refractive error.

4. Inclusion based on pre-op Central Corneal Thickness (CCT) will be assessed according
to Residual Stromal Bed Thickness

5. BSCVA of at least 20/20 in the study eye.

6. Soft contact lens users must have removed their lenses at least two weeks prior to
baseline and follow-up measurements.

7. Hard contact lens users (PMMA or rigid gas permeable lenses) must have removed their
lenses at least four weeks prior to baseline and follow-up measurements.

8. Refractive stability must be documented by previous refractions. Spherical and
cylindrical portion of the manifest refraction must not have varied by more than 0.50
diopters over the previous 12 months.

9. Exhibits strong motivation for keeping the follow-up visits.

10. Available for evaluation at Walter Reed during the 1 year follow-up period

11. If selected, willing and available to undergo testing at Ft. Belvoir during the study
period.

12. All service members must have a signed command authorization to receive government
sponsored refractive surgery. The signed command authorization will be included in
the original application.

13. Access to transportation to meet follow-up requirements.

Exclusion Criteria:

1. Residual, recurrent or active ocular diseases or congenital corneal abnormalities in
either eye such as iritis, uveitis, keratoconjunctivitis sicca, herpetic keratitis,
vernal conjunctivitis, lagophthalmos, corneal scarring, anterior basement membrane
disease, recurrent erosions, glaucoma, previous steroid responder, occludable chamber
angles, visually significant cataracts.

2. History of any previous eye surgery or trauma, including previous refractive surgery.

3. Dry eye as reflected by Schirmer's test, subjective complaints or symptoms of dry
eye, findings during slit lamp exam that would be consistent with dry eye (e.g.
superficial punctuate keratitis).

4. Corneal thickness insufficient to allow the residual remaining stromal bed to be no
less than 300 microns in each eye. The residual stromal bed thickness will be
determined by subtracting both the LASIK flap thickness and depth of the ablation
from the total central corneal thickness measured by pachymetry.

5. Female subjects who are pregnant, breast-feeding or intend to become pregnant during
the study. This is standard of care exclusion for refractive surgery at the Walter
Reed Refractive Surgery Center because of the medications that are routinely given as
part of the procedures. Standard of care analgesia consists of medications (e.g.
narcotics) labeled as Pregnancy Category "C" by the FDA. Teratogenic effects are not
known, however, physical dependence in the neonate may occur if the mother is given
narcotics. Female subjects will be given a urine pregnancy test prior to
participating in the study to rule out pregnancy.

6. Concurrent topical or systemic medications that may impair healing, including
corticosteroids, antimetabolites, isotretinoin (Accutane), amiodarone hydrochloride
(Cordarone) and/or sumatripin (Imitrex).

7. Significant corneal neovascularization.

8. Progressive myopia or keratoconus.

9. Medical condition(s), which, in the judgment of the investigator, may impair healing,
including but not limited to: collagen vascular disease, autoimmune disease,
immunodeficiency diseases, and ocular herpes zoster or simplex.

10. Patients with known sensitivity or inappropriate responsiveness to any of the
medications used in the post-operative course.

11. Any physical or mental impairment which would preclude participation in any of the
examinations.

12. Inability to meet the mandated follow-up visit schedule for any reason such as duty
hours, impending deployments, or PCS.
We found this trial at
2
sites
8901 Rockville Pike
Bethesda, Maryland 20889
(301) 295-4000
Walter Reed National Military Medical Center The Walter Reed National Military Medical Center is one...
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
Fort Belvoir, Virginia 22060
?
mi
from
Fort Belvoir, VA
Click here to add this to my saved trials